Novartis AG Deferred Tax Relating To Items Charged Or Credited Directly To Equity
Novartis AG (NVS) reported Deferred Tax Relating To Items Charged Or Credited Directly To Equity of -$72.00 million for the 12-month period ending 2025-12-31, per its 20-F filed 2026-02-04.
Financial Statements › Expense Statement › Operating Expenses
ifrs-full:DeferredTaxRelatingToItemsChargedOrCreditedDirectlyToEquity · last filed 2026-02-04
| Period end | Deferred Tax Relating To Items Charged Or Credited Directly To Equity 12 month |
|---|---|
| 2025-12-31 | -$72.00M 20-F · filed 2026-02-04 |
| 2024-12-31 | -$85.00M 20-F · filed 2026-02-04 |
| 2022-12-31 | $1.00M 20-F · filed 2024-01-31 |
| 2021-12-31 | -$35.00M 20-F/A · filed 2023-05-15 |
| 2020-12-31 | $9.00M 20-F · filed 2022-02-02 |
| 2019-12-31 | -$83.00M 20-F · filed 2021-01-26 |
| 2018-12-31 | -$17.00M 20-F · filed 2020-01-29 |
| 2017-12-31 | -$101.00M 20-F · filed 2019-01-30 |
| 2016-12-31 | -$44.00M 6-K · filed 2018-01-24 |